Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Obsidian Research
Cambridge, Massachusetts, United Statesobsidiantx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead asset, OBX-115, is a TIL therapy that has shown a 50% objective response rate and 33% complete response in an ongoing melanoma trial as of December 2023. OBX-115 eliminates the need for exogenous IL-2 via membrane-bound IL-15, aiming to expand patient eligibility and reduce toxicity.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyGene therapyGenetically engineered tumor-infiltrating lymphocyte (TIL) therapy
- Industry
- Biotech
02
Partnerships
Bristol Myers SquibbVertex Pharmaceuticals
Beyond the preview
Go deeper on Obsidian Research.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Obsidian Research.